Is Alvotech’s $240 Million Capital Boost a Game Changer for Investors?
Alvotech has secured US$240 million in combined liquidity to stabilize its operations and fund its biosimilar pipeline, following a US$165 million equity raise in June 2026 and a new US$75 million term loan facility led by GoldenTree Asset Management. This capital infusion aims to address near-term liquidity constraints while supporting product launches and global expansion … Read more